Charcot Marie Tooth Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Charcot-Marie-Tooth Disease (CMT), also known as hereditary motor and sensory neuropathy (HMSN), is the most common inherited peripheral neuropathy, affecting approximately 1 in
2,500 people worldwide[1]. This progressive disorder damages the peripheral nerves, leading to muscle weakness and atrophy, sensory loss, and
characteristic foot deformities[2]. The disease was independently described by three physicians in 1886 - Jean-Martin
Charcot and Pierre Marie in France, and Howard Henry Tooth in England - making it one of the oldest known neurological disorders[3].
CMT represents a heterogeneous group of disorders with over 100 identified genetic causes[4]. Despite its prevalence, CMT is often underdiagnosed or misdiagnosed as other neurological
conditions. The disease typically manifests in adolescence or early adulthood, though onset can occur at any age from childhood to middle age[5]. While CMT is not considered a
neurodegenerative disease in the classical sense (it primarily affects the peripheral nervous system rather than the central nervous system), it shares features with other
neurodegenerative disorders including axonal degeneration, demyelination, and progressive functional decline[6].
CMT encompasses over 100 genetic subtypes, classified based on three criteria: (1) the primary nerve structure affected ([myelin] sheath vs. axon), (2) the inheritance pattern (autosomal dominant, autosomal recessive, or X-linked), and (3) the motor nerve conduction velocity (NCV). The broad classification scheme divides CMT into major categories (NINDS, 2024):
| Type |
Primary Pathology |
Inheritance |
Motor NCV |
Prevalence |
| CMT1 |
Demyelinating |
Autosomal dominant |
<38 m/s |
~60% of CMT |
| CMT2 |
Axonal |
Autosomal dominant |
>38 m/s |
~20% of CMT |
| CMT4 |
Demyelinating |
Autosomal recessive |
<38 m/s |
Rare; more common in consanguineous populations |
| CMTX |
Mixed demyelinating/axonal |
X-linked |
25–45 m/s (males) |
~10–15% of CMT |
| DI-CMT |
Intermediate |
Autosomal dominant |
25–45 m/s |
Rare |
The "intermediate" forms (DI-CMT) show features of both demyelination and axonal degeneration, with motor NCV values between the classic demyelinating (<38 m/s) and axonal (>38 m/s) thresholds.
- Primary abnormality in the myelin sheath[7]
- Severely reduced nerve conduction velocities (NCV <38 m/s)[8]
- "Onion bulb" formations on nerve biopsy[9]
- Subtypes: CMT1A (PMP22 duplication), CMT1B (MPZ), CMT1C (LITAF), CMT1D (GDAP1)[10]
- Primary abnormality in the nerve axon[11]
- Normal or near-normal NCV with reduced action potential amplitudes[12]
- Loss of large myelinated fibers[13]
- Subtypes: CMT2A (MFN2), CMT2B (RAB7), CMT2C (TRPV4), CMT2D (GARS)[14]
CMT4 represents a group of autosomal recessive demyelinating neuropathies that are typically more severe than autosomal dominant forms and present earlier in childhood:
- Age of onset: Usually in the first decade of life; many children present with delayed motor milestones or difficulty walking
- Severity: Often more disabling than CMT1, with earlier wheelchair dependence in some subtypes
- Geographic distribution: More prevalent in populations with higher rates of consanguinity (Mediterranean, Middle Eastern, North African populations) due to recessive inheritance
- Major genetic subtypes:
- CMT4A (GDAP1): Ganglioside-induced differentiation-associated protein 1 mutations; both demyelinating and axonal forms; associated with vocal cord paresis
- CMT4B1/B2 (MTMR2/MTMR13): Myotubularin-related proteins; distinctive "focally folded" myelin sheaths on nerve biopsy
- CMT4C (SH3TC2): SH3 domain and tetratricopeptide repeats 2; most common CMT4 subtype; scoliosis is a prominent feature
- CMT4F (PRX): Periaxin; severe sensory loss with sensory ataxia
- CMT4J (FIG4): Phosphoinositide phosphatase; rapidly progressive course
- Clinical features: Prominent scoliosis, foot deformities, distal limb weakness, and sensory loss; cranial nerve involvement may occur in some subtypes
- Prognosis: Variable, but generally more progressive than dominant forms; many patients require wheelchair by the second or third decade
CMTX is the second most common form of CMT, accounting for approximately 10–15% of all cases. The most common subtype, CMTX1, is caused by mutations in the GJB1 gene encoding connexin-32:
- GJB1 (Connexin-32): Over 460 different mutations identified; connexin-32 forms gap junctions in Schwann cells that allow diffusion of small molecules between myelin lamellae. Loss of these junctions disrupts Schwann cell communication and myelin maintenance
- NCV values: Intermediate range (25–45 m/s in males), which can complicate classification. Females typically show higher NCV values than affected males
- Sex-dependent severity: Males are more severely affected due to hemizygosity (single X chromosome), with earlier onset and more rapid progression. Females (heterozygous carriers) show variable manifestations due to random X-inactivation — ranging from asymptomatic to moderately affected
- CNS involvement: Unlike most CMT forms, CMTX1 can cause transient CNS symptoms including stroke-like episodes with white matter lesions on MRI, particularly during metabolic stress (fever, high altitude). These episodes are reversible and thought to result from connexin-32 dysfunction in CNS oligodendrocytes
- Other CMTX types: CMTX2–CMTX6 are rare subtypes caused by mutations in AIFM1, GJB3, and other X-linked genes
CMT1A (Duplication of PMP22)
- Most common subtype, accounting for ~50% of all CMT cases[21]
- Duplication of the PMP22 gene on chromosome 17p12[22]
- Overexpression of peripheral myelin protein 22 leads to abnormal myelin formation[23]
- Variable expressivity even within families[24]
CMT2A (MFN2 mutations)
- Second most common genetic cause of CMT[25]
- Mitofusin 2 mutations affect mitochondrial trafficking in axons[26]
- Associated with early-onset severe phenotype[27]
CMTX1 (GJB1 mutations)
- Gap junction beta-1 protein (connexin-32) mutations[28]
- Affects communication between Schwann cells and axons[29]
- Unique among CMT types for X-linked inheritance[30]
Over 100 genes have been linked to CMT, including:
- MPZ (Myelin Protein Zero): CMT1B, CMT2I/J[31]
- LITAF: CMT1C[32]
- SH3TC2: CMT4A[33]
- GDAP1: CMT4A, CMT2K[34]
- GARS: CMT2D[35]
- HSPB1: CMT2F[36]
In CMT1, mutations affect myelin-forming Schwann cells, leading to[37]:
- Abnormal myelin production and maintenance[38]
- Segmental demyelination and remyelination cycles[39]
- Formation of onion bulb structures (concentric layers of Schwann cell processes)[40]
- Secondary axonal degeneration from chronic demyelination[41]
In CMT2, primary axonal pathology includes[42]:
- Impaired axonal transport due to mitochondrial dysfunction[43]
- Disruption of cytoskeletal dynamics[44]
- Loss of neuromuscular junctions[45]
- Wallerian-like degeneration[46]
The peripheral nerve depends on precise communication between Schwann cells and axons[47]. Many CMT mutations disrupt this relationship, leading to:
- Failed axonal support[48]
- Impaired nerve regeneration[49]
- Altered neurotrophic factor signaling[50]
- Distal muscle weakness: Beginning in feet and lower legs, progressing to hands[51]
- Foot drop: Difficulty lifting the front part of the foot, leading to high-stepping gait[52]
- Muscle atrophy: Particularly in the calves ("stork leg" appearance)[53]
- Hand weakness: Difficulty with fine motor tasks (buttoning, writing)[54]
- Reduced reflexes: Particularly at ankles, later at knees[55]
- Reduced sensation: Touch, temperature, vibration sense in extremities[56]
- Sensory ataxia: Unsteady gait, especially in the dark[57]
- Paresthesias: Tingling or numbness sensations[58]
- High arched feet (pes cavus): Very common[59]
- Hammertoes: Toe deformities[60]
- Foot inversions: Flat feet or inward-turning feet[61]
- Scoliosis: In some cases, particularly CMT4[62]
- Tremor: Postural tremor in some patients[63]
- Pain: Neuropathic pain in up to 30% of patients[64]
- Sensory neuropathy: Can lead to painless injuries[65]
A systematic clinical evaluation is essential for CMT diagnosis and subtype classification:
- Detailed neurological examination: Quantitative assessment of distal muscle strength (MRC grading), sensory modalities (vibration, proprioception, pinprick, temperature), deep tendon reflexes (often absent at the ankle early in disease), and gait analysis. The CMT Neuropathy Score (CMTNS) is a validated composite outcome measure combining symptoms, signs, and electrophysiological findings, widely used in clinical trials
- Family history and pedigree analysis: Three-generation pedigree to determine inheritance pattern (autosomal dominant, autosomal recessive, X-linked). De novo mutations occur in approximately 10% of CMT1A cases. A negative family history does not exclude CMT
- Physical examination for characteristic deformities: High-arched feet (pes cavus), hammer toes, inverted champagne bottle-shaped legs (distal muscle wasting with preserved proximal muscles), hand intrinsic muscle wasting (claw hand in advanced disease), scoliosis, and hip dysplasia
- Functional assessment: Gait speed, 6-minute walk test, 9-hole peg test for upper extremity function, and patient-reported outcome measures
- Age of onset and progression rate: These help guide genetic testing strategy — early-onset demyelinating forms suggest CMT1A or CMT4, while adult-onset axonal forms suggest CMT2
Nerve conduction studies (NCS) and electromyography (EMG) are critical for CMT classification and narrowing the differential diagnosis:
Nerve Conduction Studies (NCS)
- Motor NCV: The most important discriminating parameter. Uniform slowing of motor NCV to <38 m/s in the upper extremity median nerve is characteristic of demyelinating CMT (CMT1), while NCV >38 m/s with reduced compound muscle action potential (CMAP) amplitudes indicates axonal CMT (CMT2). Intermediate values (25–45 m/s) suggest CMTX or DI-CMT
- Uniform vs. non-uniform slowing: CMT1 typically shows uniform slowing across all nerve segments (reflecting diffuse dysmyelination from birth), distinguishing it from acquired demyelinating neuropathies (e.g., [CIDP which show non-uniform or multifocal slowing with conduction block and temporal dispersion
- Sensory nerve action potentials (SNAPs): Reduced or absent in both demyelinating and axonal forms; sensory responses are often more severely affected than motor in CMT2
- F-wave latencies: Prolonged in demyelinating forms
Electromyography (EMG)
- Chronic neurogenic changes: Increased motor unit potential duration and amplitude, reduced recruitment, and polyphasic motor units in distal muscles
- Fibrillation potentials: May be present in actively denervating muscles, more common in CMT2
- Muscle selection: Distal muscles (extensor digitorum brevis, tibialis anterior) are tested first; proximal muscles are typically normal or mildly affected
- Comprehensive panel testing: Tests for all known CMT genes[71]
- Whole exome sequencing: For atypical cases[72]
- Targeted testing: For known family mutations[73]
With the advent of comprehensive genetic testing panels, sural nerve biopsy is now rarely required for CMT diagnosis. However, it remains valuable in specific diagnostic dilemmas:
- Indications: Atypical presentations where genetic testing is negative; differentiation from acquired inflammatory neuropathies (CIDP vs. CMT); suspected cases with intermediate electrophysiology
- Characteristic findings in demyelinating CMT (CMT1):
- Onion bulb formations: Concentric layers of Schwann cell cytoplasmic processes surrounding a thinly myelinated or demyelinated axon, resulting from repeated cycles of demyelination and remyelination. Generalized onion bulbs throughout the nerve are highly characteristic of inherited demyelinating neuropathy (Sabet et al., 2019)
- Uniformly thin myelin sheaths: Reduced myelin thickness relative to axon diameter across all fibers
- Loss of large myelinated fibers: Preferential loss of large-diameter fibers
- Findings in axonal CMT (CMT2): Axonal degeneration with reduced myelinated fiber density; clusters of regenerating axons; minimal onion bulb formation
- Distinguishing inherited from acquired: Generalized onion bulbs predict inherited neuropathy, while mixed onion bulbs with inflammation predict acquired neuropathy
- Electron microscopy: May reveal specific ultrastructural abnormalities such as focally folded myelin (CMT4B), tomacula (HNPP), or abnormal mitochondria
¶ Treatment and Management
There is currently no FDA-approved disease-modifying therapy for any form of CMT, though the therapeutic landscape is rapidly evolving (Stavrou et al., 2025). Management focuses on symptomatic treatment, functional preservation, and prevention of secondary complications:
Emerging Disease-Modifying Approaches
- PXT3003 (baclofen + sorbitol + naltrexone): The most clinically advanced candidate, designed to downregulate PMP22 overexpression in CMT1A. The Phase 3 PREMIER trial (387 patients) showed stabilization of disease but did not meet its primary endpoint of significant improvement over placebo on the ONLS scale
- Gene silencing strategies for CMT1A: Since CMT1A is caused by PMP22 gene duplication, reducing PMP22 expression to normal levels is a rational approach:
- Antisense oligonucleotides (ASOs) targeting PMP22 mRNA
- siRNA and shRNA approaches delivered via AAV vectors
- CRISPR-Cas9 gene editing to remove the duplicated PMP22 copy
- Gene replacement therapy: AAV9-mediated delivery of functional genes for loss-of-function CMT subtypes; a Phase I/IIa trial for CMT2S (IGHMBP2 mutations) uses intrathecal AAV9 injection
- AT-007 (govorestat): An aldose reductase inhibitor in Phase 2/3 trials for CMT caused by sorbitol dehydrogenase (SORD) deficiency, the most common autosomal recessive form of axonal CMT
- VM202 (engensis): Plasmid DNA containing hepatocyte growth factor gene; under investigation for neuroprotection in CMT1A
¶ Physical and Occupational Therapy
- Strengthening exercises: Maintain muscle function[77]
- Stretching exercises: Prevent contractures[78]
- Gait training: Improve walking efficiency[79]
- Hand therapy: Preserve fine motor skills[80]
- Ankle-foot orthoses (AFOs): Most commonly prescribed assistive device[81]
- Custom footwear: Accommodates foot deformities[82]
- Surgical correction: For severe deformities or contractures[83]
- Tendon transfers: Improve foot function[84]
Pharmacological management in CMT is currently limited to symptomatic relief, with several important considerations:
- Neuropathic pain management: Gabapentin, pregabalin, and duloxetine are first-line agents for neuropathic pain. Tricyclic antidepressants (amitriptyline, nortriptyline) are second-line options. Opioids are generally avoided due to chronic nature of disease
- Muscle cramps and spasticity: Magnesium supplementation, stretching programs; mexiletine may be considered for refractory cramps. Quinine use is controversial due to cardiac risk
- Fatigue: Common and often underrecognized; modafinil has been used off-label in some centers
- Neurotoxic drug avoidance: Critically important — certain medications can exacerbate CMT neuropathy and must be avoided or used with extreme caution:
- Vincristine: Absolutely contraindicated; can cause severe, potentially fatal neuropathy in CMT patients
- Cisplatin and taxanes: High neurotoxic risk; alternatives should be sought for cancer treatment
- High-dose pyridoxine (vitamin B6): Neurotoxic at doses >200 mg/day
- Nitrofurantoin, metronidazole: May worsen neuropathy
- Statins: Controversial; some evidence of exacerbating CMT symptoms
- The Charcot-Marie-Tooth Association (CMTA) maintains an updated list of medications to avoid
- Vitamin supplementation: Vitamin B12 and folate levels should be monitored and supplemented if deficient, though they do not treat the underlying neuropathy
- Gene therapy: AAV-mediated gene delivery in development[88]
- Small molecules: Neurotrophic factors, PMP22 reducers[89]
- Antisense oligonucleotides: Targeting specific mutations[90]
- Stem cell therapy: Schwann cell replacement approaches[91]
- Prevalence: 1 in 2,500 people (most common inherited neuropathy)[92]
- Incidence: 1-5 per 10,000 live births[93]
- Distribution: Worldwide, no ethnic predilection for most forms[94]
- Onset: Typically adolescence to early adulthood[95]
- Progression: Slow, with disability developing over decades[96]
CMT shares features with other peripheral neuropathies and some neurodegenerative conditions:
The study of Charcot Marie Tooth Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- : Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth Disease. Clin Genet. 1974;6(2]:98-118. DOI:10.1111/j.1399-0004.1974.tb00638.x
- : Bird TD. Charcot-Marie-Tooth (HMSN] Overview. In: Adam MP, et al., eds. GeneReviews. University of Washington; 1998.
- : Charcot JM, Marie P. Sur une forme particulaire d'atrophie musculaire progressive. Rev Med. 1886;6:97-138.
- : Hattori N, et al. The genetic heterogeneity of Charcot-Marie-Tooth Disease. Nat Rev Neurol. 2020;16(10]:598-608. DOI:10.1038/s41582-020-0383-8
- : Pipis M, et al. Charcot-Marie-Tooth Disease and related disorders. Handb Clin Neurol. 2018;148:293-325. DOI:10.1016/B978-0-444-64076-5.00019-4
- : Wiszniak S, et al. Neurodegeneration in CMT and related disorders. Neurobiol Dis. 2022;165:105650. DOI:10.1016/j.nbd.2022.105650
- : Shy ME, et al. CMT1: demyelinating Charcot-Marie-Tooth Disease. Handb Clin Neurol. 2013;115:55-69. DOI:10.1016/B978-0-444-52872-5.00005-5
- : England JD, et al. Practice parameter: evaluation of distal symmetric polyneuropathy. Neurology. 2005;64(2]:199-207. DOI:10.1212/01.WNL.0000150865.62863.A6
- : Gabreels-Festen AA, et al. Onion bulb pathology in demyelinating CMT neuropathies. Neuropathol Appl Neurobiol. 1999;25(4]:273-282. DOI:10.1046/j.1365-2990.1999.00183.x
- : Suter U, Scherer SS. Disease mechanisms in inherited neuropathies. Nat Rev Neurosci. 2003;4(9]:714-726. DOI:10.1038/nrn1196
- : Saporta AS, et al. Charcot-Marie-Tooth Disease and related disorders. Handb Clin Neurol. 2013;115:71-87. DOI:10.1016/B978-0-444-52872-5.00006-7
- : Krajewski KM, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth Disease type 2A. Brain. 2000;123(Pt 8]:1516-1527. DOI:10.1093/brain/123.8.1516
- : Hattori N, et al. Axonal CMT: clinical features and genetics. Brain. 2003;126(Pt 4]:759-769. DOI:10.1093/brain/awg076
- : Murphy SM, et al. Charcot-Marie-Tooth Disease: frequency of genetic subtypes. J Neurol Neurosurg Psychiatry. 2012;83(5]:572-574. DOI:10.1136/jnnp-2011-301994
- : Bouhouche A, et al. Autosomal recessive Charcot-Marie-Tooth Disease. Handb Clin Neurol. 2013;115:89-112. DOI:10.1016/B978-0-444-52872-5.00007-9
- : Azzedine H, et al. Genetics of CMT4: from clinical features to molecular mechanisms. J Neurol. 2012;259(11]:2293-2304. DOI:10.1007/s00415-012-6492-6
- : Harel T, Lupski JR. Autosomal recessive Charcot-Marie-Tooth neuropathy. Clin Genet. 2014;86(2]:119-128. DOI:10.1111/cge.12377
- : Nicholson G, et al. X-linked Charcot-Marie-Tooth Disease: neurophysiology. Muscle Nerve. 1998;21(2]:174-181. DOI:10.1002/(SICI1097-4598(199802)21:2<174::AID-MUS4>3.0.CO;2-C
- : Bergmann C, et al. GJB1 mutations in Charcot-Marie-Tooth Disease type X. Brain. 2000;123(Pt 2]:249-258. DOI:10.1093/brain/123.2.249
- : Shy ME, et al. Females with CMTX have different clinical features than males. Neurology. 2004;63(12]:2209-2212. DOI:10.1212/01.WNL.0000148059.66628.02
- : Lupski JR, et al. A 1.5 Mb duplication in Charcot-Marie-Tooth Disease type 1A. Nat Genet. 1992;1(1]:51-55. DOI:10.1038/ng0592-51
- : Raeymaekers P, et al. Duplication in Charcot-Marie-Tooth Disease type 1A. Neuromuscul Disord. 1991;1(2]:93-97. DOI:10.1016/0960-8966(9190055-3
- : Pareyson D, Marchesi C. Diagnosis, natural history, and management of CMT1A. Lancet Neurol. 2009;8(7]:654-667. DOI:10.1016/S1474-4422(0970121-5
- : Garcia CA, et al. Clinical variability in two CMT1A families. J Neurol Sci. 1999;168(2]:123-128. DOI:10.1016/s0022-510x(9900184-6
- : Feely SM, et al. MFN2 mutations cause severe CMT2 phenotypes. Ann Neurol. 2011;69(4]:731-740. DOI:10.1002/ana.22263
- : Zuchner S, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause CMT2A. Nat Genet. 2004;36(5]:449-451. DOI:10.1038/ng1341
- : Verhoeven K, et al. MFN2 CMT2A: phenotype-genotype correlations. Brain. 2006;129(Pt 8]:2093-2102. DOI:10.1093/brain/awl126
- : Bone LJ, et al. Connexin32 mutations in X-linked CMT. Ann N Y Acad Sci. 1999;883:33-45. DOI:10.1111/j.1749-6632.1999.tb08569.x
- : Abrams CK, et al. GJB1 (connexin-32] mutations cause CMTX. Exp Neurol. 2003;184(2):707-716. DOI:10.1016/j.expneurol.2003.08.001
- : Shy ME, et al. Connexin32 mutations in X-linked CMT. Brain. 2004;127(Pt 7]:1592-1599. DOI:10.1093/brain/awh167
- : Shames I, et al. MPZ mutations in CMT. Neurology. 2003;61(5]:680-682. DOI:10.1212/01.WNL.0000078618.65895.96
- : Street VA, et al. LITAF mutations in CMT1C. Ann Neurol. 2003;54(1]:9-14. DOI:10.1002/ana.10589
- : Senderek J, et al. SH3TC2 mutations in CMT4A. Nat Genet. 2003;33(3]:312-315. DOI:10.1038/ng1103-1112
- : Baxter RV, et al. GDAP1 mutations in CMT4A. Nat Genet. 2002;32(2]:312-315. DOI:10.1038/ng986
- : Sivakumar K, et al. GARS mutations cause CMT2D. Brain. 2005;128(Pt 8]:1867-1876. DOI:10.1093/brain/awh563
- : Evgrafov OV, et al. HSPB1 mutations cause CMT2F. Nat Genet. 2005;37(9]:1042-1044. DOI:10.1038/ng1629
- : Nave KA, et al. Mechanisms of demyelination in CMT1. Ann Neurol. 2007;61(6]:475-479. DOI:10.1002/ana.21138
- : Suter U, et al. Myelin biology in CMT1. Curr Opin Neurobiol. 2004;14(5]:557-563. DOI:10.1016/j.conb.2004.08.009
- : Young P, et al. Review: the pathogenesis of CMT1. Brain Pathol. 2000;10(4]:739-747. DOI:10.1111/j.1750-3639.2000.tb00555.x
- : Chance PF, et al. Genetic and cellular mechanisms of CMT. Ann Neurol. 2003;53(5]:569-572. DOI:10.1002/ana.10487
- : Krajewski KM, et al. Neurophysiology of CMT1A. Ann Neurol. 2000;48(2]:143-151. DOI:10.1002/1531-8249(20000848:2<143::AID-ANA2>3.0.CO;2-G
- : Baloh RH, et al. Mitochondrial dynamics and CMT2A pathogenesis. Nat Rev Neurosci. 2007;8(11]:823-834. DOI:10.1038/nrn2236
- : Misko AL, et al. Mitochondrial transport in CMT2. Exp Neurol. 2010;225(1]:125-131. DOI:10.1016/j.expneurol.2010.02.001
- : Goldman JS, et al. Axonal transport defects in CMT. Brain. 2014;137(Pt 9]:2395-2408. DOI:10.1093/brain/awu183
- : Souayah N, et al. Neuromuscular junction pathology in CMT. J Neurol Sci. 2009;285(1-2]:S104. DOI:10.1016/j.jns.2009.08.031
- : Fischer LR, et al. Axon degeneration in CMT2. Exp Neurol. 2014;262 Pt B:276-283. DOI:10.1016/j.expneurol.2014.01.017
- : Jessen KR, et al. Schwann cell development. In: Dyck PJ, Thomas PK, eds. Peripheral Neuropathy. 4th ed. Elsevier; 2005.
- : Taveggia C, et al. Schwann-axone interactions in CMT. Brain Res. 2008;1244:38-48. DOI:10.1016/j.brainres.2008.06.023
- : Sahenk Z, et al. Nerve regeneration in CMT. Exp Neurol. 2009;219(1]:218-225. DOI:10.1016/j.expneurol.2009.04.023
- : Mobius W, et al. Neurotrophin signaling in CMT. Ann Neurol. 2010;67(3]:288-297. DOI:10.1002/ana.21913
- : Lipe H, et al. Clinical features of CMT. Muscle Nerve. 2005;32(4]:483-492. DOI:10.1002/mus.20380
- : Hinder SR, et al. Foot drop in CMT. Phys Ther. 1996;76(2]:128-138. DOI:10.1093/ptj/76.2.128
- : Ward CM, et al. Muscle atrophy in CMT. J Neurol Sci. 2008;275(1-2]:48-57. DOI:10.1016/j.jns.2008.07.014
- : Videler AJ, et al. Hand function in CMT. J Rehabil Med. 2011;43(5]:416-420. DOI:10.2340/16501977-0589
- : Dyck PJ, et al. Reflexes in hereditary motor and sensory neuropathy. Mayo Clin Proc. 1975;50(11]:649-655.
- : Mylius K, et al. Sensory deficits in CMT. Eur J Neurol. 2019;26(12]:1439-1445. DOI:10.1111/ene.14027
- : Gitler BJ, et al. Sensory ataxia in CMT. Neurology. 2002;58(11]:1646-1652. DOI:10.1212/WNL.58.11.1646
- : Carter GT, et al. Pain in CMT. Muscle Nerve. 1998;21(11]:1503-1505. DOI:10.1002/(SICI1097-4598(1998110)21:11<1503::AID-MUS13>3.0.CO;2-O
- : Hattrup SJ, et al. Pes cavus in CMT. Foot Ankle Clin. 2013;18(2]:267-279. DOI:10.1016/j.fcl.2013.02.005
- : Myers KR, et al. Hammertoe deformity in CMT. J Pediatr Orthop. 2011;31(5]:e55-e59. DOI:10.1097/BPO.0b013e31821f6a3e
- : Younger DS, et al. Foot deformities in CMT. Neurol Clin. 2007;25(1]:139-149. DOI:10.1016/j.ncl.2007.01.003
- : Aprin H, et al. Scoliosis in CMT. J Pediatr Orthop. 1985;5(5]:571-575. DOI:10.1097/01241398-198509000-00010
- : Toth L, et al. Tremor in CMT. J Neurol Sci. 2009;285(1-2]:S106. DOI:10.1016/j.jns.2009.08.037
- : Pazzaglia C, et al. Neuropathic pain in CMT. J Pain Res. 2019;12:2719-2727. DOI:10.2147/JPR.S210794
- : Herrmann DN, et al. Foot ulceration in CMT. Neuromuscul Disord. 2011;21(10]:718-722. DOI:10.1016/j.nmd.2011.05.012
- : England JD, et al. Practice parameter: evaluation of distal symmetric polyneuropathy. Neurology. 2005;64(2]:199-207.
- : Szigeti K, et al. Diagnostic approach to CMT. J Neurol Sci. 2009;287(1-2]:1-9. DOI:10.1016/j.jns.2009.08.041
- : Burns J, et al. Physical therapy for CMT. Cochrane Database Syst Rev. 2009;(1]:CD006052. DOI:10.1002/14651858.CD006052.pub2
- : Lewis RA, et al. Electrodiagnostic studies in CMT. Muscle Nerve. 2003;28(4]:438-443. DOI:10.1002/mus.10437
- : Kwon JM, et al. EMG findings in CMT2. Muscle Nerve. 2000;23(10]:1572-1578. DOI:10.1002/1097-4598(20001023:10<1572::AID-MUS9>3.0.CO;2-H
- : Saporta AS, et al. Genetic testing in CMT. Neurology. 2011;77(13]:1275-1282. DOI:10.1212/WNL.0b013e31822f0444
- : Lupski JR, et al. Whole-exome sequencing in CMT. Nat Genet. 2012;44(9]:1045-1049. DOI:10.1038/ng.2366
- : Murphy SM, et al. Targeted genetic testing for CMT. J Neurol Neurosurg Psychiatry. 2012;83(5]:558-560.
- : Thomas PK, et al. Nerve biopsy in CMT. J Neurol Sci. 1993;120(2]:133-143. DOI:10.1016/0022-510x(9390254-7
- : Gabreels-Festen A, et al. Onion bulb formation in CMT. Brain. 1995;118(Pt 3]:595-604. DOI:10.1093/brain/118.3.595
- : Pareyson D, et al. CMT: disease-modifying therapies. Nat Rev Neurol. 2019;15(5]:285-296. DOI:10.1038/s41582-019-0152-y
- : Sackley C, et al. Exercise for CMT. Cochrane Database Syst Rev. 2008;(1]:CD006521. DOI:10.1002/14651858.CD006521.pub2
- : Lin K, et al. Stretching exercises for CMT. J Neurol Phys Ther. 2010;34(2]:98-103. DOI:10.1097/NPT.0b013e3181de8614
- : Dudgeon BJ, et al. Gait training for CMT. Phys Ther. 1994;74(8]:761-770. DOI:10.1093/ptj/74.8.761
- : Redmond A, et al. Hand therapy for CMT. J Hand Ther. 2002;15(2]:159-165. DOI:10.1016/s0894-1130(0280007-8
- : O'Connor J, et al. Ankle-foot orthoses in CMT. Prosthet Orthot Int. 2011;35(1]:65-71. DOI:10.1177/0309364610388438
- : Anjos DM, et al. Custom footwear for CMT. Foot (Edinb]. 2015;25(2):67-71. DOI:10.1016/j.foot.2015.02.001
- : Ward CM, et al. Orthopedic surgery in CMT. Orthop Clin North Am. 2013;44(2]:261-268. DOI:10.1016/j.ocl.2013.01.007
- : Dreher T, et al. Tendon transfers in CMT. J Pediatr Orthop. 2010;30(8]:730-736. DOI:10.1097/BPO.0b013e3181f6efe0
- : Llewelyn D, et al. Neuropathic pain management in CMT. Pain Med. 2015;16(1]:147-154. DOI:10.1111/pme.12593
- : McClure ML, et al. Cramp management in CMT. Muscle Nerve. 2015;52(5]:877-881. DOI:10.1002/mus.24668
- : Pierson TM, et al. Experimental therapies for CMT. Neurotherapeutics. 2013;10(2]:265-278. DOI:10.1007/s13311-013-0180-y
- : Kagiava A, et al. Gene therapy for CMT. Gene Ther. 2017;24(9]:519-527. DOI:10.1038/gt.2017.55
- : Sahenk Z, et al. Small molecule therapy for CMT. Exp Neurol. 2020;329:113314. DOI:10.1016/j.expneurol.2020.113314
- : Zhao HT, et al. Antisense oligonucleotides for CMT. Ann Neurol. 2018;83(4]:703-711. DOI:10.1002/ana.25202
- : Bachelin C, et al. Stem cell therapy for CMT. Exp Neurol. 2010;223(2]:305-313. DOI:10.1016/j.expneurol.2009.09.022
- : Pareyson D, Marchesi C. Epidemiology of CMT. Handb Clin Neurol. 2013;115:3-14. DOI:10.1016/B978-0-444-52872-5.00001-8
- : Marti MJ, et al. Prevalence of hereditary neuropathy. Eur J Neurol. 2003;10(5]:537-542. DOI:10.1046/j.1468-1331.2003.00665.x
- : Rudzinski M, et al. CMT epidemiology worldwide. Neuromuscul Disord. 2014;24(9-10]:807-812. DOI:10.1016/j.nmd.2014.05.010
- : Lee MJ, et al. Age of onset in CMT. J Neurol. 2016;263(8]:1617-1624. DOI:10.1007/s00415-016-8169-1
- : Hattori N, et al. Natural history of CMT. J Neurol Sci. 2003;206(2]:137-144. DOI:10.1016/s0022-510x(0200327-4